vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.

TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs -5.5%, a 54.9% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 128.4%). TOMPKINS FINANCIAL CORP produced more free cash flow last quarter ($31.9M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 63.6%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.

TARS vs TMP — Head-to-Head

Bigger by revenue
TMP
TMP
1.3× larger
TMP
$194.8M
$151.7M
TARS
Growing faster (revenue YoY)
TMP
TMP
+24.3% gap
TMP
152.7%
128.4%
TARS
Higher net margin
TMP
TMP
54.9% more per $
TMP
49.4%
-5.5%
TARS
More free cash flow
TMP
TMP
$19.0M more FCF
TMP
$31.9M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
63.6%
TMP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TARS
TARS
TMP
TMP
Revenue
$151.7M
$194.8M
Net Profit
$-8.4M
$96.2M
Gross Margin
Operating Margin
-5.3%
71.7%
Net Margin
-5.5%
49.4%
Revenue YoY
128.4%
152.7%
Net Profit YoY
63.8%
388.9%
EPS (diluted)
$-0.17
$6.72

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
TMP
TMP
Q4 25
$151.7M
$194.8M
Q3 25
$118.7M
$87.4M
Q2 25
$102.7M
$82.6M
Q1 25
$78.3M
$81.7M
Q4 24
$66.4M
$77.1M
Q3 24
$48.1M
$76.6M
Q2 24
$40.8M
$72.7M
Q1 24
$27.6M
$72.8M
Net Profit
TARS
TARS
TMP
TMP
Q4 25
$-8.4M
$96.2M
Q3 25
$-12.6M
$23.7M
Q2 25
$-20.3M
$21.5M
Q1 25
$-25.1M
$19.7M
Q4 24
$-23.1M
$19.7M
Q3 24
$-23.4M
$18.6M
Q2 24
$-33.3M
$15.7M
Q1 24
$-35.7M
$16.9M
Operating Margin
TARS
TARS
TMP
TMP
Q4 25
-5.3%
71.7%
Q3 25
-12.2%
35.6%
Q2 25
-21.6%
34.2%
Q1 25
-33.5%
31.6%
Q4 24
-36.8%
33.4%
Q3 24
-52.3%
32.0%
Q2 24
-81.6%
28.3%
Q1 24
-136.5%
30.4%
Net Margin
TARS
TARS
TMP
TMP
Q4 25
-5.5%
49.4%
Q3 25
-10.6%
27.1%
Q2 25
-19.8%
26.0%
Q1 25
-32.1%
24.1%
Q4 24
-34.8%
25.5%
Q3 24
-48.7%
24.3%
Q2 24
-81.6%
21.6%
Q1 24
-129.4%
23.2%
EPS (diluted)
TARS
TARS
TMP
TMP
Q4 25
$-0.17
$6.72
Q3 25
$-0.30
$1.65
Q2 25
$-0.48
$1.50
Q1 25
$-0.64
$1.37
Q4 24
$-0.57
$1.39
Q3 24
$-0.61
$1.30
Q2 24
$-0.88
$1.10
Q1 24
$-1.01
$1.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
TMP
TMP
Cash + ST InvestmentsLiquidity on hand
$417.3M
$132.8M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$938.4M
Total Assets
$562.2M
$8.7B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
TMP
TMP
Q4 25
$417.3M
$132.8M
Q3 25
$401.8M
$193.5M
Q2 25
$381.1M
$212.6M
Q1 25
$407.9M
$193.1M
Q4 24
$291.4M
$134.4M
Q3 24
$317.0M
$132.3M
Q2 24
$323.6M
$70.9M
Q1 24
$298.5M
$57.1M
Total Debt
TARS
TARS
TMP
TMP
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
TARS
TARS
TMP
TMP
Q4 25
$343.4M
$938.4M
Q3 25
$335.1M
$788.8M
Q2 25
$332.6M
$761.8M
Q1 25
$342.5M
$741.4M
Q4 24
$224.5M
$713.4M
Q3 24
$237.5M
$719.9M
Q2 24
$252.2M
$674.6M
Q1 24
$275.2M
$667.9M
Total Assets
TARS
TARS
TMP
TMP
Q4 25
$562.2M
$8.7B
Q3 25
$534.6M
$8.5B
Q2 25
$495.0M
$8.4B
Q1 25
$500.8M
$8.2B
Q4 24
$377.0M
$8.1B
Q3 24
$376.3M
$8.0B
Q2 24
$376.8M
$7.9B
Q1 24
$349.3M
$7.8B
Debt / Equity
TARS
TARS
TMP
TMP
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
TMP
TMP
Operating Cash FlowLast quarter
$19.3M
$38.9M
Free Cash FlowOCF − Capex
$13.0M
$31.9M
FCF MarginFCF / Revenue
8.6%
16.4%
Capex IntensityCapex / Revenue
4.2%
3.6%
Cash ConversionOCF / Net Profit
0.40×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M
$105.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
TMP
TMP
Q4 25
$19.3M
$38.9M
Q3 25
$18.3M
$34.9M
Q2 25
$-29.4M
$18.9M
Q1 25
$-20.7M
$22.2M
Q4 24
$-22.2M
$95.0M
Q3 24
$-8.7M
$21.2M
Q2 24
$-14.4M
$27.3M
Q1 24
$-37.8M
$23.2M
Free Cash Flow
TARS
TARS
TMP
TMP
Q4 25
$13.0M
$31.9M
Q3 25
$16.3M
$33.9M
Q2 25
$-30.4M
$18.3M
Q1 25
$-21.2M
$20.9M
Q4 24
$-22.3M
$88.8M
Q3 24
$-8.9M
$18.9M
Q2 24
$-15.4M
$26.3M
Q1 24
$-38.0M
$21.9M
FCF Margin
TARS
TARS
TMP
TMP
Q4 25
8.6%
16.4%
Q3 25
13.8%
38.8%
Q2 25
-29.6%
22.1%
Q1 25
-27.1%
25.5%
Q4 24
-33.5%
115.1%
Q3 24
-18.6%
24.7%
Q2 24
-37.8%
36.2%
Q1 24
-137.5%
30.0%
Capex Intensity
TARS
TARS
TMP
TMP
Q4 25
4.2%
3.6%
Q3 25
1.6%
1.1%
Q2 25
1.0%
0.8%
Q1 25
0.8%
1.7%
Q4 24
0.1%
8.1%
Q3 24
0.6%
2.9%
Q2 24
2.5%
1.3%
Q1 24
0.6%
1.9%
Cash Conversion
TARS
TARS
TMP
TMP
Q4 25
0.40×
Q3 25
1.47×
Q2 25
0.88×
Q1 25
1.13×
Q4 24
4.82×
Q3 24
1.14×
Q2 24
1.74×
Q1 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons